GeneDx Holdings WGS Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $442.68M+34.1% | $427.54M+40.0% | $402.19M+50.5% | $362.32M+48.7% | $330.14M+48.8% | ||
| $134.77M+17.5% | $129.37M+16.5% | $122.08M+12.7% | $118.91M+10.8% | $114.68M+4.6% | ||
| $307.91M+42.9% | $298.17M+53.4% | $280.11M+76.2% | $243.41M+78.5% | $215.46M+92.1% | ||
| 69.6%+4.3pp | 69.7%+6.1pp | 69.6%+10.2pp | 67.2%+11.2pp | 65.3%+14.7pp | ||
| $79.25M+69.6% | $72.03M+57.5% | $59.07M+27.4% | $50.91M+3.9% | $46.73M-15.4% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $0-100% | ||
| -$2.62M+14.9% | -$2.54M+16.3% | -$2.72M— | -$3M— | -$3.08M— | ||
| -$11.48M+52.7% | -$8.06M+72.6% | -$7.46M— | -$3.9M— | -$24.29M— | ||
| —— | —— | —— | —— | —— | ||
| -$77.81M— | -$21.02M— | —— | —— | —— | ||
| -17.6%— | -4.9%— | —— | —— | —— | ||
| -$2.66— | -$0.73— | —— | —— | —— | ||
| 116.5M+7.1% | 115.3M+8.1% | 113.6M+9.1% | 111.9M+8.9% | 108.8M+7.1% | ||
| 115.4M+6.1% | 114.2M+7.0% | 112.4M+8.0% | 110.7M+7.7% | 108.8M+7.1% | ||
| -$2.62M+14.9% | -$2.54M+16.3% | -$2.72M— | -$3M— | -$3.08M— | ||
| —— | —— | -$4.3M+60.6% | -$1.78M+81.1% | -$8.37M-466% | ||
| -$78.03M— | -$20.92M— | —— | —— | —— | ||
| $72.9M+25.0% | $48.03M+8.7% | $55.86M-7.3% | $59.06M+27.6% | $58.32M+7.9% | ||
| -$69.36M-71.8% | -$61.52M-104% | -$50.96M-47.8% | -$54.03M-0.3% | -$40.38M+4.8% | ||
| -$6.22M-227% | $36.37M+228% | $33.19M+160% | $13.02M+114% | -$1.9M+98.7% | ||
| —— | —— | —— | —— | —— | ||
| $442.68M+34.1% | $427.54M+40.0% | $402.19M+50.5% | $362.32M+48.7% | $330.14M+48.8% | ||
| -$39.64M— | $12.15M— | —— | —— | —— | ||
| -9%— | 2.8%— | —— | —— | —— | ||
| -$66M— | -$13.08M— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is GeneDx Holdings's revenue?
- GeneDx Holdings (WGS) generated $442.7M in revenue over the trailing twelve months, up 34.1% year over year.
- Is GeneDx Holdings profitable?
- GeneDx Holdings is not currently profitable: it reported a net loss of $77.8M over the trailing twelve months, a -17.6% net margin.
- What are GeneDx Holdings's profit margins?
- Gross margin is 69.6% and operating margin is -14.9%, with a -17.6% net margin.
- What is GeneDx Holdings's earnings per share?
- GeneDx Holdings's diluted EPS over the trailing twelve months is $-2.68.
- Where does GeneDx Holdings's income statement data come from?
- Every line is extracted from GeneDx Holdings's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
